TScan Therapeutics, Inc.
TCRX
$1.08
$0.032.38%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 35.66% | 3.36% | -8.28% | 4.70% | -19.81% |
| Total Depreciation and Amortization | -5.74% | 9.89% | 2.95% | -4.64% | -30.77% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -26.96% | 9.11% | 15.75% | -7.42% | 98.77% |
| Change in Net Operating Assets | -3,192.76% | -193.01% | 106.05% | -221.39% | 1,984.95% |
| Cash from Operations | 1.42% | 2.41% | 11.49% | -37.12% | 1.81% |
| Capital Expenditure | 88.00% | -11.42% | 16.51% | -72.52% | 35.18% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -55.88% | -31.61% | 230.08% | -46.55% | 134.80% |
| Cash from Investing | -54.48% | -32.75% | 258.00% | -50.43% | 133.14% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -100.00% | -- | -- | -69.27% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | 100.00% | 85.71% | -101.75% | -- |
| Cash from Financing | -- | -100.00% | 122.10% | -101.15% | 3,614.63% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -15,367.86% | -99.27% | 162.19% | -153.94% | 141.79% |